TISIDB

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
Domain	PF00619 Caspase recruitment domain PF00625 Guanylate kinase
Function	Acts as a scaffolding protein that can activate the inflammatory transcription factor NF-kappa-B and p38/JNK MAP kinase signaling pathways. Forms a signaling complex with BCL10 and MALT1, and activates MALT1 proteolytic activity and inflammatory gene expression. MALT1 is indispensable for CARD14-induced activation of NF-kappa-B and p38/JNK MAP kinases (PubMed:11278692, PubMed:21302310, PubMed:27113748, PubMed:27071417). May play a role in signaling mediated by TRAF2, TRAF3 and TRAF6 and protects cells against apoptosis. ; FUNCTION: Isoform 3: Not able to activate the inflammatory transcription factor NF-kappa-B and may fuction as a dominant negative regulator (PubMed:21302310, PubMed:26358359).

> Gene Ontology [ TOP ]
Biological Process	GO:0007250 activation of NF-kappaB-inducing kinase activity GO:0032147 activation of protein kinase activity GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0033674 positive regulation of kinase activity GO:0034612 response to tumor necrosis factor GO:0038061 NIK/NF-kappaB signaling GO:0045860 positive regulation of protein kinase activity GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0071356 cellular response to tumor necrosis factor GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:1901222 regulation of NIK/NF-kappaB signaling GO:1901224 positive regulation of NIK/NF-kappaB signaling
Molecular Function	GO:0050700 CARD domain binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04064 NF-kappa B signaling pathway
Reactome	-

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CARD14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CARD14 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CARD14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.943	0.0242
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.411	0.601
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.334	0.0311
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.53	0.16
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.455	0.823
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.62	0.803
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.326	0.443
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.235	0.792
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.385	0.705
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.746	0.0573
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.759	0.146
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.072	0.697

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CARD14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CARD14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CARD14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CARD14. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CARD14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CARD14 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CARD14 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CARD14
Name	caspase recruitment domain family, member 14
Aliases	CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location	17q25.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CARD14 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CARD14